1st February 2024
Barzolvolimab Significantly Decreases Chronic Spontaneous Urticaria Disease Activity and is Well Tolerated: Top Line Results from a Phase 2 Trial
1st November 2023
Barzolvolimab Demonstrates Safety and Clinically Meaningful Activity in Moderate-Severe Prurigo Nodularis
1st October 2023
Patients With Chronic Spontaneous Urticaria Experience Improvement in Quality of Life When Treated With Barzolvolimab
1st June 2023
Barzolvolimab Demonstrates Clinical Activity in a Multiple Ascending Dose Trial in Chronic Spontaneous Urticaria
1st February 2023
Safety and Clinical Activity of Multiple Doses of Barzolvolimab, an anti-KIT Antibody, in Patients with Chronic Spontaneous Urticaria
1st December 2022
Multi-dosed barzolvolimab is effective in chronic spontaneous urticaria
1st December 2022